e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Airways disease comorbidities and general aspects
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease
E. D. Bateman, D. Singh, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Cape Town, South Africa; Manchester, London, United Kingdom; Barcelona, Spain; , United States Of America)
Source:
Annual Congress 2011 - Airways disease comorbidities and general aspects
Session:
Airways disease comorbidities and general aspects
Session type:
Thematic Poster Session
Number:
4005
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. D. Bateman, D. Singh, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Cape Town, South Africa; Manchester, London, United Kingdom; Barcelona, Spain; , United States Of America). The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eur Respir J 2011; 38: Suppl. 55, 4005
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy of tiotropium bromide in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Source: Eur Respir J 2003; 21: 912
Year: 2003
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 23: 241-249
Year: 2004
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012
Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004
Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Source: Eur Respir J 2011; 38: 797-803
Year: 2011
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Once-daily QVA149 has a good safety profile in patients with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Source: Eur Respir J 2002; 19: 936-943
Year: 2002
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept